Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ADC Therapeutics

Allogene Therapeutics Inc

BioNTech SE

Legend Biotech

Y-Mabs Therapeutics Inc

Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutralizing antibody, 47D11, to AbbVie.

Week In Review: Week's China Life Science Investments Total $800 Million

Bancroft Fund Ltd

BlackRock Health Sciences Trust II

Eaton Vance Tax-Advantaged Dividend Income Fund

Horizon Technology Finance

Gladstone Land

NextEra Energy

November started out with a bang due to the election. Besides some early buying last month, it was another month of light buying throughout the remainder of November.

November Buys: 3 Monthly Paying CEFs, Plus Some Dividend Growth Opportunities

AbbVie (NYSE: ABBV) shares have advanced from $80 above $109 since the beginning of November, and the current price stands around $103. The company has reported better than expected results in Q3 and increased the quarterly dividend by 10.2%.

Abbvie shares remain in focus for investors after the company increased the dividend by 10.2%

AbbVie (ABBV) gets positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rinvoq for treating active psoriatic arthritis and active ankylosing spondylitis.

AbbVie's (ABBV) Rinvoq Gets CHMP Nod for Two New Indications

Archrock

Altria

Simon Property Group

AT&T

Another wave of COVID wave is upon us, with cases in various states rising to new record levels and shutdowns proliferating. Dividend Growth Stocks have historically offered reliable income that can see you through tough times. They have a history of outperforming during recessions and market troubles.

Ride Through Another COVID Wave With These 5 Undervalued Dividend Growth Stocks

Kraft Heinz

Things are looking up, but investors who prepare now for another nosedive may find great returns in these two companies.

2 High-Yielding Dividend Stocks to Buy if the Market Crashes Again

AbbVie stock has surged since my last post, gaining 28% to trade at $107 at the time of writing. Q320 results returned the company to profitability - an impressive achievement given the integration of Allergan assets and pandemic pressures.

AbbVie: No Sense Of (Post) Humira Failure - My Price Target Is $120 - $150

NORTH CHICAGO, Ill., Dec. 11, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of RINVOQ™ (upadacitinib, 15 mg), an oral, once daily selective and reversible...

CHMP Recommends the Approvals of RINVOQ™ (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis

Bristol-Myers

Johnson & Johnson

Merck

Pfizer

Many prognosticators across Wall Street feel that interest rates will start to rise in 2021 Deutsche Bank is negative on duration and sees the 10-year Treasury bond yield rising to 1.5% in the second quarter of 2021 from the current yield of 0.95%.

5 Dividend-Paying Pharmaceutical Stocks to Buy for Solid 2021 Total Return

NORTH CHICAGO, Ill., Dec. 10, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced top-line results from the Phase 3b Heads Up study showing that upadacitinib (30 mg, once daily) achieved superiority to dupilumab (300 mg, every other week) for the primary endpoint, the proportion of...

RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis

AbbVie's (ABBV) phase III U-ACHIEVE study evaluating Rinvoq for treating patients with moderate to severe ulcerative colitis achieves the primary goal. The study also met all secondary endpoints.

AbbVie's (ABBV) Rinvoq Meets Goal in Ulcerative Colitis Study

NORTH CHICAGO, Ill., Dec. 9, 2020 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, is investing $50 million in a five-year program to support underserved Black communities across the United States. AbbVie will collaborate with six nonprofit partners, including...

AbbVie Announces Partners in $50 Million Program to Promote Health and Education Equity in Underserved Black Communities

Healthcare stocks are a staple of every portfolio. With an ageing population, healthcare stocks are here to stay.

Pfizer Vs. Merck Vs. AbbVie Vs.

British American Tobacco

Enterprise Products Partners

Magellan Midstream Partners

Just because the S&P 500 is 40% historically overvalued, doesn't mean you can't still find plenty of Buffett style "fat pitch" high-yield blue-chip bargains. 9/12 quality blue-chip BTI yields a safe 7.2%, is 51% undervalued, and analysts expect it could deliver 5-year total returns of 20.5% CAGR, 7.3X that of the S&P 500.

4 Buffett Fat Pitch High-Yield Blue-Chip Bargains Set To Soar

Aurora Cannabis

Cronos Group

GW Pharmaceuticals

Medicinal cannabis is no longer speculative. There are truly impactful treatments out there, as well as investment-worthy marijuana stocks.

7 Medical Marijuana Stocks for a Healthcare Revolution

Ford Motor Company

Gogo

Goldman Sachs

Nautilus

QUALCOMM

Almost everyone likes cheap stocks, because as investors, we don't like to overpay. Some are value traps, while others are treasure chests.

7 Cheap Stocks to Buy Before the Market Realizes their Worth

NORTH CHICAGO, Ill., Dec. 6, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), today announced results from a long-term integrated analysis of two Phase 3 clinical studies and additional pooled analysis evaluating the effect of IMBRUVICA (ibrutinib) based therapies for the first-line treatment of...

Combined Data from Multiple Phase 3 Studies of IMBRUVICA® (ibrutinib) Show Efficacy and Safety in High-Risk, Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Real-World Data Indicating Low Biomarker Testing Rates for These Patients

The Oracle of Omaha knows a good bargain when he sees one.

3 Value Stocks Warren Buffett Owns That You Should Consider Buying Too

NORTH CHICAGO, Ill., Dec. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new, updated results from the Phase 3 MURANO and CLL14 clinical trials evaluating VENCLEXTA®/VENCLYXTO® (venetoclax) fixed duration treatment combinations at the virtual 62nd American Society of...

AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL)

NORTH CHICAGO, Ill., Dec. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial evaluating IMBRUVICA® (ibrutinib) in combination with VENCLEXTA®/VENCLYXTO® (venetoclax) in previously untreated patients with chronic...

IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

Abbott Labs

These dividend stocks continue to outperform thier competition in yielding higher and consistent returns despite the impact of the pandemic The post 3 Dividend Stocks for Big Total Returns in 2021 appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets

3 Dividend Stocks for Big Total Returns in 2021

AbbVie Inc. (ABBV) Presents at Piper Sandler 32nd Annual Healthcare Conference (Transcript)

AbbVie (ABBV) signs a global deal with Frontier Medicines to make innovative therapies and E3 degraders against difficult-to-drug targets.

AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier

AbbVie (ABBV) Management on Evercore ISI 3rd Annual HealthCONx Conference

Inovio Pharmaceuticals

Novavax

Regeneron Pharmaceuticals

Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks investors should be weary of in the weeks ahead.

News for AbbVie Stock (ABBV)